Patents by Inventor Steven W. King
Steven W. King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210032340Abstract: Disclosed are surprising new methods and kits for identifying and treating patients treatable with PS-targeting antibodies, particularly for identifying and treating cancer patients using bavituximab and bavituximab combination therapies. The methods and kits are based on the surprising finding that defined ranges of pre-treatment blood concentrations of ?2-glycoprotein 1 (?2GPI), particularly functional ?2GPI, act as an indicator to accurately predict patients with better treatment outcomes.Type: ApplicationFiled: September 26, 2017Publication date: February 4, 2021Applicant: ONCOLOGIE, INC.Inventors: Min Tang, Joseph S. Shan, Steven W. King, Connie Chang, Michael A. Brown
-
Publication number: 20160311886Abstract: Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.Type: ApplicationFiled: July 12, 2016Publication date: October 27, 2016Inventors: Phillip E. Thorpe, Troy A. Luster, Steven W. King
-
Publication number: 20160015826Abstract: Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and fir treating viral infections and other diseases.Type: ApplicationFiled: February 2, 2015Publication date: January 21, 2016Inventors: Philip E. Thorpe, Troy A. Luster, Steven W. King
-
Patent number: 8956616Abstract: Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.Type: GrantFiled: January 24, 2006Date of Patent: February 17, 2015Assignees: Board of Regents, The University of Texas System, Peregrine Pharmaceuticals, Inc.Inventors: Philip E. Thorpe, Troy A. Luster, Steven W. King
-
Patent number: 8137540Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.Type: GrantFiled: August 20, 2009Date of Patent: March 20, 2012Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
-
Patent number: 7951356Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: GrantFiled: May 18, 2000Date of Patent: May 31, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Publication number: 20090312523Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.Type: ApplicationFiled: August 20, 2009Publication date: December 17, 2009Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
-
Patent number: 7591953Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.Type: GrantFiled: June 25, 2004Date of Patent: September 22, 2009Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
-
Patent number: 7101557Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: GrantFiled: February 27, 2003Date of Patent: September 5, 2006Assignee: Board of Regents The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Publication number: 20030232753Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: ApplicationFiled: February 27, 2003Publication date: December 18, 2003Applicant: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Publication number: 20030211075Abstract: Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.Type: ApplicationFiled: September 27, 2002Publication date: November 13, 2003Inventors: Philip E. Thorpe, Steven W. King, Claudia Gottstein
-
Publication number: 20030139374Abstract: Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.Type: ApplicationFiled: September 27, 2002Publication date: July 24, 2003Applicant: Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc.Inventors: Philip E. Thorpe, Steven W. King, Claudia Gottstein
-
Publication number: 20030129193Abstract: Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.Type: ApplicationFiled: September 27, 2002Publication date: July 10, 2003Applicant: Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc.Inventors: Philip E. Thorpe, Steven W. King, Claudia Gottstein
-
Publication number: 20030124132Abstract: Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.Type: ApplicationFiled: September 27, 2002Publication date: July 3, 2003Applicant: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Claudia Gottstein
-
Patent number: 6156321Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: GrantFiled: January 20, 1998Date of Patent: December 5, 2000Assignee: Board Of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Patent number: 6132729Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.Type: GrantFiled: January 20, 1998Date of Patent: October 17, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Patent number: 6132730Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.Type: GrantFiled: January 20, 1998Date of Patent: October 17, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao